These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 10789612

  • 1. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD.
    Arch Intern Med; 2000 Apr 24; 160(8):1177-84. PubMed ID: 10789612
    [Abstract] [Full Text] [Related]

  • 2. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, Rowan JP, Black DM.
    Atherosclerosis; 1996 Nov 15; 127(1):113-22. PubMed ID: 9006811
    [Abstract] [Full Text] [Related]

  • 3. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM, Capuzzi DM, Guyton JR.
    Am J Cardiol; 1998 Dec 17; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [Abstract] [Full Text] [Related]

  • 4. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP, Diabetes Multicenter Research Group.
    Arch Intern Med; 2002 Jul 22; 162(14):1568-76. PubMed ID: 12123399
    [Abstract] [Full Text] [Related]

  • 6. Lipid and transaminase concentrations after formulary conversion of Niaspan to Slo-Niacin.
    Byrd C, Mowrey KA.
    Am J Health Syst Pharm; 2010 Dec 01; 67(23):2038-42. PubMed ID: 21098376
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
    Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J.
    Am J Cardiol; 1998 Dec 17; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
    [Abstract] [Full Text] [Related]

  • 8. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
    Goldberg AC.
    Am J Cardiol; 1998 Dec 17; 82(12A):35U-38U; discussion 39U-41U. PubMed ID: 9915661
    [Abstract] [Full Text] [Related]

  • 9. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.
    N Engl J Med; 1999 Aug 05; 341(6):410-8. PubMed ID: 10438259
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM.
    Ann Intern Med; 2005 Jan 18; 142(2):95-104. PubMed ID: 15657157
    [Abstract] [Full Text] [Related]

  • 11. Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations.
    Rubins HB, Robins SJ.
    J Intern Med; 1992 Apr 18; 231(4):421-6. PubMed ID: 1588269
    [Abstract] [Full Text] [Related]

  • 12. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.
    JAMA; 2001 Mar 28; 285(12):1585-91. PubMed ID: 11268266
    [Abstract] [Full Text] [Related]

  • 13. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Mar 28; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

  • 14. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH InvestigatorsAxio Research, LLC, Seattle, WA, USA. ruthm@axioresearch.com.
    Am Heart J; 2011 Mar 28; 161(3):538-43. PubMed ID: 21392609
    [Abstract] [Full Text] [Related]

  • 15. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May 28; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH, Kim MK, Lee HY, Kang HJ, Kim YJ, Park BJ, Kim HS.
    Clin Ther; 2011 Oct 28; 33(10):1357-64. PubMed ID: 21955937
    [Abstract] [Full Text] [Related]

  • 17. Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
    McKenney JM, Barnett MD, Wright JT, Proctor JP.
    Arch Intern Med; 1992 Sep 28; 152(9):1781-7. PubMed ID: 1520045
    [Abstract] [Full Text] [Related]

  • 18. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun 28; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 19. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis.
    Knipscheer HC, Nurmohamed MT, Van den Ende A, Plaat B, Pruijs HJ, Mulder WJ, Kastelein JJ.
    J Intern Med; 1994 Oct 28; 236(4):377-84. PubMed ID: 7931040
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.